Additionally, the use of additive or synergistic therapies in the subgroup of HCC with highly activated CCN2/MAPK/Erk/Id-1 signaling could enhance current knowledge of chemotherapy and aid in developing individual treatments. This evidence concerns the gene CCN2 and hepatocellular carcinoma.